UTHR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
United Therapeutics Corp (UTHR) does not present a strong buy opportunity for a beginner investor with a long-term focus at this time. The technical indicators are neutral to slightly bearish, options data suggests bearish sentiment, and there are no recent news or significant catalysts to drive immediate upside. While analysts have shown confidence in the long-term potential of the company's pipeline, the recent price trend and lack of positive signals from Intellectia Proprietary Trading Signals do not support an immediate buy decision.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 30.565, and moving averages are converging, showing no clear trend. The stock is trading near its S1 support level of 536.127, with resistance at 545.822. Overall, the technical indicators suggest a neutral to slightly bearish outlook.
Analysts have expressed confidence in the company's long-term prospects, particularly with the potential of Tyvaso in idiopathic pulmonary fibrosis and other pulmonary indications. Wells Fargo and Raymond James have issued price targets as high as $735 and $700, respectively, reflecting optimism in the company's competitive position and product pipeline.
The stock has shown a -2.70% regular market change, and the MACD indicates bearish momentum. Options data suggests bearish sentiment, with a high put-call volume ratio. Additionally, there are no recent news or event-driven catalysts to drive immediate upside.
No financial data or valuation metrics are available for analysis. The latest quarter financials are not provided.
Analysts' ratings are mixed. While Morgan Stanley maintains an Equal Weight rating with a lowered price target of $516, Wells Fargo and Raymond James have issued Overweight and Outperform ratings with price targets as high as $735 and $700, respectively. This reflects long-term confidence but does not align with the current price trend.
